Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00203528 · ClinicalTrials.gov registry record · Phase 4
Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder
A Phase 4 study, sponsored by Tuscaloosa Research & Education Advancement Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00203528: Completed Phase 4 study, sponsored by Tuscaloosa Research & Education Advancement Corporation.
NCT00203528 is a Phase 4 study that has completed, run by Tuscaloosa Research & Education Advancement Corporation. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00203528, a Phase 4 study, has completed, sponsored by Tuscaloosa Research & Education Advancement Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the safety and efficacy of divalproex extended release (ER) compared to risperidone in the treatment of bipolar disorder with comorbid substance use disorder
Interventions
- DRUG risperidone
- DRUG divalproex sodium ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-01 |
| Est. Completion | 2007-02 |
| Phase | Phase 4 |
What the finished NCT00203528 record still lists
NCT00203528 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which risperidone is the first listed.
NCT00203528 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00203528 about?
NCT00203528 is a clinical study titled "Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder". The primary objective is to evaluate the safety and efficacy of divalproex extended release (ER) compared to risperidone in the treatment of bipolar disorder with comorbid substance use disorder
What is the current status of trial NCT00203528?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2004-01. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00203528?
The interventions under investigation include: risperidone (DRUG), divalproex sodium ER (DRUG).
Who is sponsoring clinical trial NCT00203528?
This trial is sponsored by Tuscaloosa Research & Education Advancement Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00203528's enrollment target sits among peer trials
30 1552nd of 2000 higher than 367 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia